StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/305% above fair value
$65.83−2.46 (-3.60%)

Close on Nov 19, 2026Market cap $16.06BP/E 19.7Yield –

Exelixis net income

Net income is the profit left for shareholders after every expense, interest and tax.

Exelixis's net income for the twelve months ending Oct 2, 2026 was $885.14M, up 30.6% year over year. For fiscal 2025 it was $782.57M, up 50.1% from the year before. The highest annual figure on record is $782.57M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Jan 2, 2026$782.57M+50.1%
FY2024Jan 3, 2025$521.27M+150.9%
FY2023Dec 29, 2023$207.77M+14.0%
FY2022Dec 30, 2022$182.28M-21.1%
FY2021Dec 31, 2021$231.06M+106.7%
FY2020Jan 1, 2021$111.78M-65.2%
FY2019Jan 3, 2020$321.01M-53.5%
FY2018Dec 28, 2018$690.07M+347.4%
FY2017Dec 29, 2017$154.23M–
FY2016Dec 31, 2016-$70.22M–
FY2015Dec 31, 2015-$161.74M–
FY2014Dec 31, 2014-$261.30M–
FY2013Dec 31, 2013-$238.19M–
FY2012Dec 31, 2012-$145.34M-292.0%
FY2011Dec 31, 2011$75.70M–
FY2010Dec 31, 2010-$92.33M–
FY2009Dec 31, 2009-$135.22M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$218.10M+12.7%
Q2 FY2026Jul 3, 2026$212.05M+14.7%
Q1 FY2026Apr 3, 2026$210.47M+31.9%
Q4 FY2025Jan 2, 2026$244.53M+74.8%
Q3 FY2025Oct 3, 2025$193.58M+64.1%
Q2 FY2025Jul 4, 2025$184.85M-18.3%
Q1 FY2025Apr 4, 2025$159.62M+327.7%
Q4 FY2024Jan 3, 2025$139.86M+63.5%
Q3 FY2024Sep 27, 2024$117.97M+11232.7%
Q2 FY2024Jun 28, 2024$226.12M+178.5%
Q1 FY2024Mar 29, 2024$37.32M-6.8%
Q4 FY2023Dec 29, 2023$85.52M–
Q3 FY2023Sep 29, 2023$1.04M-98.6%
Q2 FY2023Jun 30, 2023$81.18M+14.9%
Q1 FY2023Mar 31, 2023$40.03M-41.6%
Q4 FY2022Dec 30, 2022-$30.17M-131.7%
Q3 FY2022Sep 30, 2022$73.21M+91.6%
Q2 FY2022Jul 1, 2022$70.67M-26.5%
Q1 FY2022Apr 1, 2022$68.57M+4183.1%
Q4 FY2021Dec 31, 2021$95.17M+235.2%
Q3 FY2021Oct 1, 2021$38.20M–
Q2 FY2021Jul 2, 2021$96.09M+43.8%
Q1 FY2021Apr 2, 2021$1.60M-96.7%
Q4 FY2020Jan 1, 2021$28.39M-58.7%
Q3 FY2020Oct 2, 2020-$32.04M-132.9%
Q2 FY2020Jul 3, 2020$66.82M-15.5%
Q1 FY2020Apr 3, 2020$48.61M-35.8%
Q4 FY2019Jan 3, 2020$68.74M-80.9%
Q3 FY2019Sep 27, 2019$97.45M-23.0%
Q2 FY2019Jun 28, 2019$79.04M-9.7%
Q1 FY2019Mar 29, 2019$75.78M-34.6%
Q4 FY2018Dec 28, 2018$360.09M+835.6%
Q3 FY2018Sep 28, 2018$126.63M+55.6%
Q2 FY2018Jun 29, 2018$87.49M+395.5%
Q1 FY2018Mar 30, 2018$115.86M+593.8%
Q4 FY2017Dec 29, 2017$38.49M+9.6%
Q3 FY2017Sep 30, 2017$81.38M–
Q2 FY2017Jun 30, 2017$17.66M–
Q1 FY2017Mar 31, 2017$16.70M–
Q4 FY2016Dec 31, 2016$35.12M–

More Exelixis figures

See a number that looks wrong?